Trial reportScientific reports2021
Preliminary clinical experience applying donor-derived cell-free DNA to discern rejection in pediatric liver transplant recipients.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- Characterizing Early Donor-Derived cfDNA Kinetics in Stable Pediatric Living-Donor Liver Transplant Recipients.Pediatric transplantation · 2026Article
- Monitoring Inflammatory Markers and Anti-α-Gal Antibodies in Liver Transplant Recipients: Implications for Infection and Rejection.Diagnostics (Basel, Switzerland) · 2026Article
- Dynamic kinetics of graft-derived cell-free DNA and personalized tacrolimus target ranges for acute rejection monitoring in pediatric liver transplantation.Frontiers in pharmacology · 2026Article
- Donor-derived cell-free DNA as a noninvasive biomarker for diagnosis and monitoring of acute rejection after liver transplantation.Frontiers in immunology · 2026Article
- Damage-associated molecular patterns in hepatic ischemia-reperfusion injury: spatiotemporal signatures, biomarker potential, and clinical translation.Frontiers in immunology · 2026Review
- Advances in donor-derived cell-free DNA monitoring for solid organ transplantation.Frontiers in immunology · 2026Review
- Diagnostic and predictive biomarkers of acute rejection after liver transplantation.International journal of surgery (London, England) · 2025Review
- Advances and challenges in the application of donor-derived cell-free DNA for diagnosis and treatment in liver transplantation: a narrative review.BMC surgery · 2025Review
- Utility ofAnnals of nuclear medicine · 2025Article
- Donor-derived cell-free DNA and miRNA monitoring for the early prediction and diagnosis of liver allograft rejection and patient outcomes.Frontiers in immunology · 2025Observational
- The role ofQuantitative imaging in medicine and surgery · 2024Article
- A review of cell-free DNA and epigenetics for non-invasive diagnosis in solid organ transplantation.Frontiers in transplantation · 2024Review
- Analysis of the primary factors influencing donor derived cell-free DNA testing in kidney transplantation.Frontiers in immunology · 2024Review
- Application of graft-derived cell-free DNA for solid organ transplantation.Frontiers in immunology · 2024Review
- Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation.Annals of transplantation · 2023Review
- The methylome and cell-free DNA: current applications in medicine and pediatric disease.Pediatric research · 2023Review
- Article
- Assessing Donor Liver Quality and Restoring Graft Function in the Era of Extended Criteria Donors.Journal of clinical and translational hepatology · 2023Review
- Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients.BMC pulmonary medicine · 2023Article
- European Society of Organ Transplantation Consensus Statement on Testing for Non-Invasive Diagnosis of Kidney Allograft Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Donor-derived cell-free DNA (dd-cfDNA) has been of major interest recently as a non-invasive marker of graft injury, but has not yet been extensively tested in children. From May to September in 2019, a total of 76 pediatric patients receiving a liver graft were enrolled and there were 27 patients excluded. Ultimately plasma samples and matched liver specimens from 49 patients were successfully collected whenever rejection was suspected clinically. Dd-cfDNA were analyzed and then compared to biopsy. Of these, 11 (22.4%) patients were found to have rejection by biopsy. Dd-cfDNA levels were higher among patients with rejection compared to those with no rejection. In subgroup analysis, dd-cfDNA% among patients with rejection differed from those with EBV/CMV infection and DILI patients. Similarly, observations were available concerning dd-cfDNA (cp/mL). The AUC for dd-cfDNA% and dd-cfDNA (cp/mL) were 0.878, 0.841, respectively, both of which were higher than conventional LFTs. For rejection, dd-cfDNA% ≥ 28.7% yielded a sensitivity of 72.7%, specificity 94.7% and dd-cfDNA (cp/mL) ≥ 2076 cp/mL, yielded a sensitivity of 81.8%, specificity 81.9%. Of note, the dd-cfDNA distribution was significantly different between whole liver and LLS transplantation. In the setting of pediatric LTx, dd-cfDNA appears to be a sensitive biomarker indicating the presence of rejection.International Clinical Trails Registry Platform: ChiCTR1900022406.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.